These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 30204048)

  • 21. Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
    Blinova E; Roshchin D; Kogan E; Samishina E; Demura T; Deryabina O; Suslova I; Blinov D; Zhdanov P; Osmanov U; Nelipa M; Kaprin A
    Cells; 2019 May; 8(6):. PubMed ID: 31159302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research.
    Suto H; Funakoshi Y; Nagatani Y; Imamura Y; Toyoda M; Kiyota N; Matsumoto H; Tanaka S; Takai R; Hasegawa H; Yamashita K; Matsuda T; Kakeji Y; Minami H
    J Cancer Res Ther; 2021; 17(6):1358-1369. PubMed ID: 34916366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in Lung Cancer.
    Du L; Herbst RS; Morgensztern D
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
    Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
    Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.
    Zhou K; Guo S; Tong S; Sun Q; Li F; Zhang X; Qiao Y; Liang G
    Stem Cells Dev; 2018 Sep; 27(17):1191-1202. PubMed ID: 29978730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
    J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human CD141
    Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
    Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
    J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
    Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Pennacchioli E; Cocorocchio E; Ferrucci PF; De Marinis F; Gelber RD; Goldhirsch A
    J Natl Cancer Inst; 2019 Aug; 111(8):772-781. PubMed ID: 31106827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of PD-1/PD-L1¬†immune checkpoint inhibitors and PD-L1¬†testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors.
    Le CT; Murphy WJ
    J Immunother Cancer; 2019 Nov; 7(1):291. PubMed ID: 31699145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy.
    Wu C; Wang X; Shang H; Wei H
    Dis Markers; 2022; 2022():1479246. PubMed ID: 36072895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.